Cancer

Cell culture studies identified a nicotonic acetylcholine receptor α7 (CHRNA7) antagonist that could help treat glioblastoma, lung adenocarcinoma and neuroblastoma. Chemical synthesis and cell-based testing of structural hybrids of a stilbene-based nAchR inhibitor tool compound and a previously reported resveratrol-based mitochondrial-targeted compound yielded a compound that bound human CHRNA7 with a Ki of 164 nM and inhibited growth in human glioblastoma, lung adenocarcinoma and neuroblastoma cell lines with IC₅₀ values of 0.11, 0.49 and 10 μM, respectively. Next steps could include testing the compound in animal models of those cancers...